Last reviewed · How we verify
VNRX-5133
VNRX-5133 is a Small molecule drug developed by Venatorx Pharmaceuticals, Inc.. It is currently in Phase 1 development.
VNRX-5133 is a pharmaceutical drug being studied for safety and pharmacokinetics in various conditions, including bacterial infections and urinary tract infections. According to ChEMBL, the mechanism of action of VNRX-5133 is unknown, but it is related to taniborbactam, a β-lactamase inhibitor that works by inhibiting bacterial β-lactamases.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | VNRX-5133 |
|---|---|
| Sponsor | Venatorx Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections (PHASE3)
- Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects (PHASE1)
- VNRX-5133 With VNRX-5022 in Subjects With Varying Degrees of Renal Impairment (PHASE1)
- VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers (PHASE1)
- VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VNRX-5133 CI brief — competitive landscape report
- VNRX-5133 updates RSS · CI watch RSS
- Venatorx Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about VNRX-5133
What is VNRX-5133?
Who makes VNRX-5133?
What development phase is VNRX-5133 in?
Related
- Manufacturer: Venatorx Pharmaceuticals, Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing